市場調查報告書
商品編碼
1268931
2023-2030 年全球超聲支氣管內活檢市場Global Endobronchial Ultrasound Biopsy Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球超聲支氣管內活檢市場預計將實現利潤豐厚的增長,到 2022 年將達到 5.767 億美元,到 2030 年將達到 8.327 億美元。 在預測期內(2023 年至 2030 年),該市場的複合年增長率為 4.8%。 徑向探頭支氣管內超聲活檢(RP-支氣管內超聲活檢)和引導鞘(GS)為基礎的活檢技術經常用於周圍肺部病變的診斷。
近年來,低溫活檢、電磁感應支氣管鏡、超薄支氣管鏡等技術相繼出現,用於肺部疾病的精準診斷。 縱隔鏡檢查,縱隔淋巴結取樣,比超聲支氣管內活檢-TBNA 侵入性更小,也可用於肺門淋巴結取樣,可作為輕度鎮靜的門診手術進行。
超聲支氣管內活檢市場在過去幾年中取得了巨大的技術進步,創造了能夠提供更準確、更快結果的新工具和方法。 這些發展使超聲支氣管內活檢成為識別肺癌和其他呼吸系統疾病的首選方法。 由於超聲活檢無放射性且無痛,因此該市場有望實現高速增長。
超聲支氣管內活檢市場的增長率正在增加對微創手術的需求,由於其具有與開放手術相比疼痛更小、恢復更快、並發症更少等諸多優點,因此呈現出高增長率各種因素。 超聲支氣管內活檢的趨勢是一種侵入性較小的手術,這使其成為患者和醫療保健專業人員的理想選擇。 需要及早發現肺癌以改善患者預後並降低死亡率。
不斷上升的肺癌患病率和研發正在推動超聲支氣管內活檢市場的增長。
隨著肺癌患病率的上升,超聲支氣管內活檢的全球市場正在擴大。 根據 2022 年肺癌狀況報告,儘管 5 年生存率 (61%) 明顯更高,但只有 26% 的肺癌病例被早期發現。 然而,44% 的病例發現得太晚,只有 7% 的病例存活下來。 煙草使用導致高達 90% 的肺癌發病率,長期使用煙草預計會增加全球癌症發病率,尤其是在中國、俄羅斯和印度等發展中國家。
主要參與者正在擴大對技術先進的產品(例如經支氣管抽吸針)的研發工作。 這是由於對診斷工具的需求不斷增長,以充分檢測與肺部相關的感染和癌症。 目前,多家公司正在投資並做出重大努力,以開發更好的用於診斷目的的超聲活檢產品。
不斷增加的醫療保健投資正在為製造商創造有利可圖的增長前景。
由於超聲支氣管內活檢在呼吸系統疾病診斷和肺部感染總體患病率方面的接受度越來越高,因此存在巨大的市場機會。 對診斷性經支氣管穿刺針和活檢鉗等產品的需求將為製造商提供有利可圖的增長選擇。
冷凍活檢、超薄膜支氣管鏡和電磁引導支氣管鏡等新技術剛剛出現,有助於準確檢測肺部疾病。 超聲支氣管鏡經支氣管淋巴結抽吸 (TBNA) 也用於肺門淋巴結取樣,可作為輕度鎮靜的門診手術進行,但在縱隔內進行的縱隔鏡檢查侵入多於檢查。 因此,增加對醫療保健基礎設施的投資和支出有助於市場的增長。
支氣管內活檢非常昂貴,而且價格因地區、醫療機構和保險範圍而異。 支氣管內活檢的費用可能令患者望而卻步,尤其是在醫療費用較低的欠發達國家。
超聲支氣管內活檢的費用可分為多項費用,包括使用的設備、治療本身以及所需的善後護理。 根據您的醫療系統和國家/地區,您的保險可能會支付全部或部分治療費用。
COVID-19 分析包括 COVID 前情景、COVID 情景、COVID 後情景、價格動態(與 COVID 前情景相比,大流行期間和之後的價格變化)、供需範圍(需求和供應變化由於貿易限制、封鎖和隨後的問題),政府舉措(政府機構為振興市場、部門和行業所做的努力)、製造商的戰略舉措(為緩解 COVID 問題製造商做了什麼?)也進行了解釋。
俄羅斯對烏克蘭發動無法無天、毫無抵抗的全面入侵,美國和聯合國對俄羅斯實施制裁。 由於危機,許多公司已開始暫停在俄羅斯的業務。 隨著公司開始退出俄羅斯市場,制裁無疑將對全球市場產生重大影響。 由於金融監管惡化,俄烏戰爭將對俄羅斯醫療器械行業產生負面影響。
The global endobronchial ultrasound biopsy market reached US$ 576.7 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 832.7 million by 2030. The market is growing at a CAGR of 4.8% during the forecast period (2023-2030). To diagnose peripheral pulmonary lesions, radial probe endobronchial ultrasound biopsy (RP-endobronchial ultrasound biopsy ) and guide sheath (GS)-based biopsy methods are utilized frequently.
Cryo biopsy, electromagnetic navigational bronchoscopy, and ultrathin bronchoscopy have recently been developed to aid in the precise diagnosis of lung illnesses. The mediastinal LN sampling, mediastinoscopy, is less invasive than endobronchial ultrasound biopsy -TBNA, which can also be used to sample hilar lymph nodes and can be done as an outpatient procedure with light sedation.
In the endobronchial ultrasound biopsy market, over the past few years, technology has advanced drastically, with new tools and methods being created that give more precision and quicker outcomes. Because of these developments, endobronchial ultrasound biopsy is now the method of choice for identifying lung cancer and other respiratory conditions. The ultrasound biopsy market will see high growth as it doesn't use radiation and is painless.
The endobronchial ultrasound biopsy market growth rate is high owing to various factors such as increasing demand for minimally invasive procedures because they have a number of advantages over open surgeries, such as less pain, quicker recovery, and fewer complications. Endobronchial ultrasound biopsy trend is seen as it is a less invasive technique which makes it desirable for both patients and healthcare professionals. To improve patient outcomes and lower mortality rates, lung cancer must be detected early.
The increasing prevalence of lung cancer and research and development drives the growth of the endobronchial ultrasound biopsy market.
The global market for endobronchial ultrasound biopsy is expanding as a result of the rising prevalence of lung cancer. Only 26% of lung cancer cases are identified at an early stage, despite the fact that the five-year survival rate is substantially higher (61%), according to the State of Lung Cancer 2022 Report. However, 44% of cases are discovered far too late, when just 7% of them survive. Up to 90% of occurrences of lung cancer are attributable to tobacco use, and prolonged usage is expected to increase the incidence of cancer worldwide, especially in developing countries like China, Russia, and India.
Key players are expanding their research and development efforts for technologically advanced products such as transbronchial aspiration needles. This is happening as a result of the rising demand for diagnostic tools for proper detection of lung related infections or cancer. Several firms are currently investing and putting a lot of effort in developing better ultrasound biopsy products for diagnostic purposes.
The growing investments in healthcare create lucrative growth prospects for manufacturers.
There is a sizable market opportunity for endobronchial ultrasound biopsy as it is becoming more widely accepted for the diagnosis of respiratory disorders and because the overall prevalence of lung infections is rising. Manufacturers are going to have profitable choices for growth as demand for products like transbronchial aspiration needles or biopsy forceps for diagnosis will be required.
To assist in the accurate detection of lung diseases, new technologies such as cryo biopsy, ultrathin bronchoscopy, and electromagnetic navigational bronchoscopy were just recently created. The endobronchial ultrasonography biopsy, or TBNA, which may be utilized as well for sampling hilar lymph nodes & can be performed as an outpatient operation with mild sedation, is more intrusive than mediastinoscopy, which takes place inside the mediastinum. Hence, rising investments or healthcare infrastructure spending are contributing to the growth of the market.
An endobronchial ultrasound biopsy can be expensive, and the price can change depending on the area, the medical center, and insurance coverage. In some circumstances, patients may find the expense of an endobronchial ultrasound biopsy to be exorbitant, especially in underdeveloped nations where healthcare spending is minimal.
The price of an endobronchial ultrasound biopsy procedure can be broken down into a number of different costs, including those for the tools used, the treatment itself, and any required aftercare. Depending on the health plan and the nation, insurance may occasionally pay all or part of the cost of the treatment.
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).
Russia started its unlawful and unprovoked full-scale invasion of Ukraine, which resulted in sanctions against Russia from the US, the UN, and other nations. In light of the current crisis, many businesses are starting to stop operating in Russia. These sanctions will surely have a significant effect on the worldwide market as businesses start to leave the Russian market. Due to worsening financial restrictions, the Russo-Ukrainian War will have a detrimental effect on the medical device industry in Russia.
The global endobronchial ultrasound biopsy market is segmented based on product type, application, End User and region.
Lung cancer diagnosis segment will dominate the global endobronchial ultrasound biopsy market over the forecast period, owing to the rise in patients with lung cancer. Lung cancer, infections, and other disorders affecting enlarged lymph nodes in the chest can all be identified with endobronchial ultrasonography (EBUS), a minimally invasive but extremely efficient method.
EBUS enables doctors to use a method known as transbronchial needle aspiration (TBNA) to retrieve tissue or fluid samples from the lungs and adjacent lymph nodes without requiring traditional surgery. The samples can be used to identify tumours like lymphoma, diagnose and stage lung cancer, find infections, and diagnose inflammatory diseases that damage the lungs, such as sarcoidosis.
For instance, Olympus offers 19G EBUS-TBNA needles in addition to the 21G, 22G, and 25G needles, which is unmatched in the industry. The business also offers the ViziShot2 FLEX 19G, a second-generation EBUS needle that assists with histology sampling for suspected cases of lymphoma and sarcoidosis while also supplying more tissue for cutting-edge molecular analysis that enables targeted lung cancer treatment.
North America holds 39.8% of market share owing to the strong presence of major players and increasing healthcare infrastructure investment.
Manufacturers have chances to expand their operations in this region because of the rising demand for diagnostic tools for lung infections in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of endobronchial ultrasound biopsy, which has increased the demand.
Growth is also fueled by government measures to promote technologically advanced biopsy tools. Another issue is the rapidly expanding population with lung cancer, which has increased demand for cutting-edge, diagnostic and treatment tools. The region is growing as healthcare professionals have good knowledge about the endobronchial ultrasound biopsy tool, and they are adopting it highly for diagnosis of lung related issues among people.
The major global players in the endobronchial ultrasound biopsy market include Olympus Corporation, CLINODEVICE, Medtronic, CONMED Corporation, Boston Scientific Corporation, Medi-Globe GmbH, Serpex Medical, MICRO-TECH (Nanjing) Co., Ltd., Cook Group Incorporated, and ACE Medical Devices Pvt. Ltd. among others.
The global endobronchial ultrasound biopsy market report would provide approximately 53 tables, 54 figures and 195 Pages.
Australia
LIST NOT EXHAUSTIVE